THC

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), which specializes in transdermal synthetic cannabinoid treatments, has a 25-percent probability for success in its treatment of adult epilepsy, an analyst said Tuesday. Cantor Fitzgerald analyst Elemer Piros said there were no surprises in the Q2 results...

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine. Risk Mitigation Through Diversification The company announced Tuesday positive top...

H.C. Wainwright & Co. believes that the current valuation of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has not taken into consideration the potential increased success rate of ZYN002 for epilepsy. Therefore, the firm believes the stock has the potential to deliver more than 60 percent upside...